<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle18
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:1105731980;
mso-list-template-ids:1591126304;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1
{mso-list-id:1530142249;
mso-list-template-ids:1607629614;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2
{mso-list-id:1659965481;
mso-list-template-ids:1460165930;}
@list l2:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3
{mso-list-id:1705985738;
mso-list-template-ids:321797394;}
@list l3:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l3:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4
{mso-list-id:1885175441;
mso-list-template-ids:-1050908786;}
@list l4:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l4:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5
{mso-list-id:2002805326;
mso-list-template-ids:283702752;}
@list l5:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.nsf.gov/pubs/2021/nsf21057/nsf21057.jsp?WT.mc_id=USNSF_25&WT.mc_ev=click">NSF Dear Colleague Letter: Tool Development for Cell Biology (Tools4Cells)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">As scientists’ abilities to open new frontiers in cell biological research continue to be limited by current technologies, there is still a need for the development of new tools and methods
to advance our understanding of cells, especially using interdisciplinary approaches that can leverage advances in other fields and apply them to cell biology. Technological advancements have had a profound and catalytic influence on the field of cell biology,
either through the application of existing technologies to the study of cellular processes in new and creative ways, or through the development of novel technologies to study areas not previously possible. Relatively recent examples of such advances include:
methods of molecular dynamics simulations to study membrane protein signal transmission; gene-editing technologies such as CRISPR/Cas9 applied to probe gene localization; development of new single molecule fluorescence/microscopy techniques to enable in vivo
single cell dynamic measurements; single cell sequencing; and the application of cryo-EM and x-ray free electron lasers to the study of protein structure and dynamics. The purpose of this Dear Colleague Letter (DCL) is to encourage submission of proposals
to develop novel tools and methods that improve scientists’ abilities to manipulate, control, analyze, or measure critical aspects of cells and their functions in order to open new areas of study in cell biology. Proposals for new tools or methods developments
in cell biology can include, but are not limited to the general areas of <b><i>bioinformatics, instrumentation, or laboratory or field-based research methods</i></b>. Proposals should be submitted to one of two Divisions in the Directorate for Biological Sciences
(BIO) depending on the range of applicability of the tool or method and its connection to a specific research question rather than a general topical area. The research cluster and program within the two BIO divisions that seek proposals in this area are:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l0 level1 lfo3"><i><span style="font-size:12.0pt;font-family:Palatino">Cellular Dynamics and Function Cluster</span></i><span style="font-size:12.0pt;font-family:Palatino"> in BIO’s Division of Molecular and Cellular Biology
(MCB) if the proposed tool or method addresses a specific research question or hypothesis defined by and to be used by an individual user or group of researchers. Such a project would be evaluated on the
<b>importance of the research question or hypothesis</b> and the <b>potential of the tool or method</b> to improve scientists’ ability to study cells or their function related to the question or hypothesis. In addition, for some efforts, the research community
is encouraged to take risks in exploring new tools or methods with the potential to change understanding of how cells work.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo3"><i><span style="font-size:12.0pt;font-family:Palatino">Infrastructure Innovation for Biological Research Program</span></i><span style="font-size:12.0pt;font-family:Palatino"> in BIO’s Division of Biological
Infrastructure (DBI) if the proposed tool or method is applicable to a broad class of biological research questions or topics and will meet the needs of a well-defined community of researchers. Such a project would be evaluated on its
<b>responsiveness to a well-defined research question in BIO, the specific BIO-funded research community that would benefit</b>, a clear
<b>demonstration of how the innovation represents an advance over currently available tools or methods</b>, and the quality of the
<b>project management description</b>. Although this DCL is encouraging submissions related to cell biology, this program and all other DBI programs invite proposals on any area of biology that fit within its guidelines.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Proposals responsive to this DCL should be submitted as follows based on the above criteria:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l4 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=504861&org=MCB&from=home">Cellular Dynamics and Function Cluster</a> via the MCB core solicitation
(currently <a href="https://www.nsf.gov/publications/pub_summ.jsp?ods_key=nsf21509">
NSF 21-509</a>). However, for the projects that are “high-risk/high-payoff”, investigators should consider the Early-Concept Grants for Exploratory Research (EAGER) type of proposal which allows requests for up to $300,000 over two years. Specific instructions
for preparation and submission of EAGER proposals can be found in Chapter II.E.2 of the
<i><a href="https://www.nsf.gov/publications/pub_summ.jsp?ods_key=nsf20001">NSF Proposal & Award Policies & Procedures Guide</a></i> (PAPPG).<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l4 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=505459&org=DBI&from=home">Infrastructure Innovation for Biological Research Program</a> via the
DBI solicitation (currently <a href="https://www.nsf.gov/publications/pub_summ.jsp?WT.z_pims_id=505459&ods_key=nsf21502">
NSF 21-502</a>).<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Proposals may be submitted at any time.
<span style="color:red">Med-RA deadline to receive draft documents: 10 business days before submission to sponsor.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.michaeljfox.org/grant/promoting-diversity-equity-and-inclusion-parkinsons-disease-research?pn_cid=pn-a1b1R000009f2O3.">Michael J. Fox Foundation: Promoting Diversity,
Equity and Inclusion in Parkinson’s Disease Research</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Michael J. Fox Foundation seeks applications with the potential to increase knowledge about Parkinson’s disease in populations that have been excluded from or underrepresented in research.
Though no definitive evidence exists that the incidence, morbidity, or mortality of Parkinson’s disease (PD) varies between socioeconomic and ethnic groups, data on traditionally underrepresented groups is either sparse or nonexistent. This request for applications
to promote diversity, equity and inclusion in Parkinson’s research is open to proposals that will increase inclusivity and broaden our understanding of PD. Such projects will help accelerate the discovery of strategies for reducing risk and developing treatments
for all people. Applicants may request budgets starting from $50,000 up to $400,000, depending on the scope of work for 18 to 36 months. Applications should focus on studies in underrepresented populations around one or more of the following Parkinson’s areas: <o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l3 level1 lfo9"><b><span style="font-size:12.0pt;font-family:Palatino">Disease burden</span></b><span style="font-size:12.0pt;font-family:Palatino">: Research toward robust estimates of PD incidence and/or prevalence<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo9"><b><span style="font-size:12.0pt;font-family:Palatino">Risk and pathology</span></b><span style="font-size:12.0pt;font-family:Palatino">: Diagnostic, biomarker, and/or pathological evaluations to better
understand Parkinson’s risk and pathology, and discern how they intersect with the social determinants of health and structural discrimination<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo9"><b><span style="font-size:12.0pt;font-family:Palatino">Assessments</span></b><span style="font-size:12.0pt;font-family:Palatino">: Evaluation of assessment procedures across different cultures and differential
response to treatment<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo9"><b><span style="font-size:12.0pt;font-family:Palatino">Clinical course</span></b><span style="font-size:12.0pt;font-family:Palatino">: Investigation of how Parkinson’s disease progresses in different populations
and likelihood of milestones for advanced disease such as cognitive impairment, refractory motor symptoms and loss of independence<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo9"><b><span style="font-size:12.0pt;font-family:Palatino">Access to care</span></b><span style="font-size:12.0pt;font-family:Palatino">: Exploration of structural barriers that prevent access to neurology evaluations
and care, and access to/uptake of device-aided therapies<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Pre-proposals due April 21, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: April 8.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-016.html">HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules
and Biologics] (R34 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The goal of this funding opportunity announcement (FOA) is to solicit Initial Analgesic Development R34 applications that propose 2-year exploratory/planning awards that are expected to
enable a future application for <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-015.html">
RFA-NS-21-015</a> HEAL Initiative: Team Research – for Initial Translational Efforts in Non-addictive Analgesic Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed). Thus, the limited scope of aims and approach of these applications
are expected to establish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay the groundwork for a subsequent Team Research U19 application. These R34 awards will support the building of a
research team to collect initial data and recruit additional collaborators. The application must include a plan for developing a strong research team, as well as a strategy to collect preliminary data linking putative therapeutic targets to the proposed pain
indication and supporting the hypothesis that altering target activity will produce desirable outcomes for the disease.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due April 27, 2021; June 22, 2021; October 13, 2021; June 9, 2022; October 11, 2022; June 9, 2023; and October 10, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for April 27, 2021 due date: April 14.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Congressionally Directed Medical Research Programs<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://cdmrp.army.mil/funding/arp" target="_blank">Autism Research Program</a><br>
<b>Clinical Trial Award</b><br>
Pre-application: May 3, 2021. Invited full application: August 5, 2021.<br>
<b>Idea Development Award</b><br>
Pre-application: May 3, 2021. Invited full application: August 5, 2021.<br>
<b>Clinical Translational Research Award</b><br>
Pre-application: May 3, 2021. Invited full application: August 5, 2021.<br>
<b>Career Development Award</b><br>
Pre-application: May 3, 2021. Invited full application: August 5, 2021.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for the above pre-applications: April 20.<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://cdmrp.army.mil/funding/prcrp" target="_blank">Peer Reviewed Cancer Research Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">FY 2021 topic areas:</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"> bladder cancer; blood cancers; brain cancer; cancers associated with the
use of beryllium; colorectal cancer; endometrial cancer, esophageal cancer; germ cell cancers; head and neck cancers; liver cancer; lymphoma, mesothelioma, and metastatic cancers; neuroblastoma, pediatric, adolescent, and young adult cancers; pediatric brain
tumors, stomach cancer; sarcoma; thyroid cancer; and the link between scleroderma and cancer.<br>
<b>Behavioral Health Science Award</b><br>
Pre-application (required letter of intent): July 29. Full application: August 18.<br>
<b>Career Development Awar</b>d <b>- Fellow Option</b><br>
Pre-application (required letter of intent): July 29. Full application: August 18.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for the above full applications: July 19.</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><br>
<b>Idea Award</b><br>
Pre-application: May 20. Invited full application: September 8.<br>
<b>Impact Award</b><br>
Pre-application: May 20. Invited full application: September 8.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for the above pre-applications: May 10.</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><br>
<b>Translational Team Science Award</b><br>
Pre-application (required letter of intent): July 29. Full application: August 18.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for full application: July 19.<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://cdmrp.army.mil/funding/prmrp" target="_blank">Peer Reviewed Medical Research Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">FY 2021 topic areas:</span></b><span style="font-size:12.0pt;font-family:Palatino"> arthritis, burn pit exposure, congenital heart disease, diabetes, dystonia, eating disorders, emerging
viral diseases, endometriosis, epidermolysis bullosa, familial hypercholesterolemia, fibrous dysplasia, focal segmental glomerulosclerosis, food allergies, Fragile X, frontotemporal degeneration, hemorrhage control, hepatitis B, hydrocephalus, hypertension,
inflammatory bowel diseases, malaria, metals toxicology, mitochondrial disease, myalgic encephalomyelitis / chronic fatigue syndrome, myotonic dystrophy, non-opioid therapy for pain management, nutrition optimization, pathogen-inactivated blood products, peripheral
neuropathy, plant-based vaccines, platelet-like cell production, polycystic kidney disease, pressure ulcers, pulmonary fibrosis, respiratory health, rheumatoid arthritis, sleep disorders and restriction, suicide prevention, sustained release drug delivery,
vascular malformations, women’s heart disease.<br>
<b>Clinical Trial Award</b><br>
Pre-application: May 13. Invited full application: August 26.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for pre-application: May 3.</span></b><span style="font-size:12.0pt;font-family:Palatino"><br>
<b>Discovery Award</b><br>
Pre-application (required letter of intent): April 29. Full application: May 13.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for full application: May 3.</span></b><span style="font-size:12.0pt;font-family:Palatino"><br>
<b>Focused Program Award</b><br>
Pre-application: May 13. Invited full application: August 26.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for pre-application: May 3.</span></b><span style="font-size:12.0pt;font-family:Palatino"><br>
<b>Investigator Initiated Research Award</b><br>
Pre-application: April 28. Invited full application: September 2.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for pre-application: April 15.</span></b><span style="font-size:12.0pt;font-family:Palatino"><br>
<b>Technology / Therapeutic Development Award</b><br>
Pre-application: April 28. Invited full application: September 2.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for pre-application: April 15.</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://cdmrp.army.mil/funding/tbdrp.aspx" target="_blank">Tick-Bourne Disease Research Program</a><br>
<b>Career Development Award</b><br>
Pre-application: May 26. Invited full application: August 27.<br>
<b>Idea Development Award</b><br>
Pre-application: May 26. Invited full application: August 27.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for the above pre-applications: May 13.</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://moore-patientcare.smapply.io/prog/request_for_proposals/" target="_blank">Gordon and Betty Moore Foundation: Development of Clinical Quality Measures to Improve Diagnosis</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">In November 2018, the Moore Foundation announced its <a href="https://www.moore.org/article-detail?newsUrlName=the-moore-foundation-invests-$85-million-to-improve-diagnostic-performance" target="_self">Diagnostic
Excellence Initiative</a>, which aims to reduce harm from erroneous or delayed diagnoses, reduce costs and redundancy in the diagnostic process, improve health outcomes, and save lives. According to the foundation, twelve million Americans experience a diagnostic
error each year, with diagnostic errors playing a role in an estimated 40,000 to 80,000 deaths annually in the United States. In other words, there is an urgent need to improve diagnosis; however, without an awareness of baseline performance and standards
against which to compare performance, there is no way to measure improvement or to gauge the results of interventions. Despite a lengthy and growing list of clinical quality measures in health care, few existing measures address diagnostic performance specifically.
The challenge of finding meaningful clinical measures for diagnosis reflects the complexity of the diagnostic process. To help address the problem, grants of up to $500,000 over eighteen months will be awarded to support the development of innovative clinical
quality measures that promote excellence in diagnosis of three categories of disease that comprise the most common and most harmful diagnostic errors, acute vascular events (such as stroke and myocardial infarction), infections (such as sepsis and pneumonia),
and cancer (such as lung and colorectal cancer). The expected work requires two interlinked activities: 1) development of the rationale for a measure; and 2) operationalizing the measure into an algorithm.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due May 10, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: April 27.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-21-005.html" target="_blank">Short Courses on Innovative Methodologies and Approaches in the Behavioral and Social Sciences
(R25 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and
clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on:<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Courses for Skills Development:</span></b><span style="font-size:12.0pt;font-family:Palatino"> For example, advanced courses in a specific discipline or research area, clinical procedures
for research, or specialized research techniques.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This FOA is to support courses for skills development in cross-cutting methodologies and analytics that are needed to advance behavioral and social sciences research (BSSR) but are not
well addressed by existing educational programs widely available to the BSSR community. Short courses supported by this FOA should develop, implement, evaluate and disseminate education and training focused on innovative methods for BSSR. Methodological domains
of focus include but are not limited to innovative data collection methodologies and analytic techniques, analysis and linking of big data, or needed but underutilized designs to advance research across the translational spectrum.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due June 4, 2021 (non-AIDS) and September 7, 2021 (AIDS).
<span style="color:red">Med-RA deadline to receive draft documents for June 4, 2021 due date: May 24.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R21 / R01 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-176.html" target="_blank">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-175.html" target="_blank">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">A growing body of evidence suggests that optimal cognitive, affective, and social processes are associated with highly coordinated neural activity. These findings indicate that oscillatory
rhythms, their co-modulation across frequency bands, spike-phase correlations, spike population dynamics, and other patterns might be useful drivers of therapeutic development for the treatment of cognitive, social, or affective symptoms in neuropsychiatric
disorders. This Funding Opportunity Announcement (FOA) supports projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing. Applications must use experimental designs that incorporate
active manipulations to address at least one, and ideally more, of the following topics: (1) in animals or humans, determine which parameters of neural coordination, when manipulated in isolation, improve particular aspects of cognitive, affective, or social
processing; (2) in animals or humans, determine how particular abnormalities at the genomic, molecular, or cellular levels affect the systems-level coordination of electrophysiological patterns during behavior; (3) determine whether
<i>in vivo</i>, systems-level electrophysiological changes in behaving animals predict analogous electrophysiological and cognitive improvements in healthy persons or clinical populations; and (4) use biologically-realistic computational models that include
systems-level aspects to understand the function and mechanisms by which oscillatory and other electrophysiological patterns unfold across the brain to impact cognitive, affective, or social processing.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires May 8, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for June 5, 2021 R01 standard date: May 24; and June 16, 2021 R21 standard date: June 3.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-167.html" target="_blank">Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not
Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This funding opportunity announcement (FOA) encourages innovative research to develop, characterize, and improve animal models, biological materials, and novel technologies to better understand
human health and disease. This FOA also seeks projects aimed at improving the diagnosis and control of diseases that interfere with animal use for biomedical research. The proposed project must have broad application to multiple NIH Institutes or Centers (ICs)
to align with the <a href="https://orip.nih.gov/">Office of Research Infrastructure Programs’ (ORIP) trans-NIH mission</a>. The proposed studies must explore multiple body systems or evaluate diseases that impact multiple body systems. Applications that develop
models focused on a specific disease or area of research, or only propose studies primarily relevant to a single NIH IC, will be considered not acceptable to this FOA and will be withdrawn.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires May 8, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for June 16, 2021 standard date: June 3.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-012.html">High-Priority Behavioral and Social Research Networks in Alzheimer’s Disease and Alzheimer’s Disease-Related
Dementias (R24 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) invites applications to develop new research and research infrastructure via networks for behavioral and social research on Alzheimer’s disease
and Alzheimer’s disease-related dementias (AD/ADRD); attract new researchers into behavioral and social research on AD/ADRD; infuse a focus on health disparities into AD/ADRD research; and address ongoing needs for harmonization and biomarker collection in
large population panel studies to support AD/ADRD research as recommended by the
<a href="https://www.nia.nih.gov/sites/default/files/2020-02/2019-BSR-Review-Committee-Report-508.pdf">
2019 BSR NACA Review</a>. Network/infrastructure-building activities include, but are not limited to: meetings to develop novel research areas and interact on the development of infrastructure; small-scale pilots; dissemination and outreach activities; and
educational activities. NIA seeks to renew critical ongoing network efforts as well as initiate new networks limited to the following priority areas: decision neuroscience and aging; measurement for dementia care in home and community-based services; the dementia
care workforce; and education and AD/ADRD.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due June 23, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: June 10.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-013.html">High-Priority Behavioral and Social Research Networks (R24 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) invites applications to develop new research and research infrastructure for life course research on aging; attract new researchers in aging;
infuse a focus on health disparities into aging research; and address ongoing needs for harmonization and biomarker collection in large population panel studies, as recommended by the
<a href="https://www.nia.nih.gov/sites/default/files/2020-02/2019-BSR-Review-Committee-Report-508.pdf">
2019 BSR NACA Review</a>. Network/infrastructure-building activities include, but are not limited to: meetings to develop novel research areas and interact on the development of infrastructure; small-scale pilots; dissemination and outreach activities; and
educational activities. NIA seeks to renew critical ongoing network efforts as well as initiate new networks limited to the following priority areas: midlife reversibility of biobehavioral risk associated with early life adversity; harmonization of Health
and Retirement Study international aging studies; biomarker collection in population studies; and innovation in longitudinal aging studies.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due June 23, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: June 10.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Data Science: Infectious and Immune-mediated Diseases (R21 / U01 Clinical Trial Not Allowed)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-035.html">Exploratory Data Science Methods and Algorithm Development in Infectious and Immune-mediated Diseases (R21 Clinical
Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to support exploratory research focused on developing innovative methods and algorithms in biomedical computing, informatics,
and data science addressing priority needs across the infectious or immune-mediated disease research continuum aligned with the research mission of NIAID. This includes infectious diseases, emerging infections, or immune-mediated diseases that include allergy,
autoimmunity, or immune reactions associated with transplantation. As a part of the trans-NIAID Data Science program, this R21 FOA encourages applications focused on the development of novel computational, mathematical, and statistical algorithms and methods,
including artificial intelligence and machine learning approaches, that can considerably improve acquisition, management, analysis, visualization, and dissemination of relevant data and/or knowledge.
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-020.html">Early-Stage Development of Data Science Technologies for Infectious and Immune-mediated Diseases (U01 Clinical
Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the development of enabling data science technologies to improve the acquisition, management,
analysis, visualization, and dissemination of data and knowledge for immune-mediated and infectious diseases including disease mechanism, risk prediction, epidemiology, detection and diagnosis, treatment and vaccines across the allergy, immune-mediated, and
infectious-disease research continuum, aligned with the research mission of NIAID. This includes infectious diseases, emerging infections, or immune-mediated diseases that include allergy, autoimmunity, or immune reactions associated with transplantation.
As a part of the trans-NIAID data science program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification
of existing tools for new applications.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due July 2, 2021; February 17, 2022; July 1, 2022; February 17, 2023; and July 6, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for July 2, 2021 due date: June 21.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-163.html">Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous
System (UG3 / UH3 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I
clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies,
and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with
NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from
the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due August 10, 2021; February 9, 2022; August 9, 2022; February 9, 2023; August 9, 2023; and February 9, 2024 plus standard AIDS dates through May 7, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for August 10, 2021 due date: July 28.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://ppc.sas.upenn.edu/sites/default/files/PrimalsResearchAwardsRFP.pdf">Primals Research Awards: Intriguing for Social, Behavioral, and Psychology Researchers</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The University of Pennsylvania Positive Psychology Center, with support from the Templeton Religion Trust, is pleased to announce the Primals Research Awards. Our goal is to promote new
empirical research exploring how primal world beliefs(‘primals’) are formed, maintained, change, or influence nontrivial outcomes or psychological processes. As recently introduced(Clifton et al., 2019;
<a href="https://tinyurl.com/y4m62r7k">https://tinyurl.com/y4m62r7k</a>), primals are basic perceptions of the general character of the world as a whole, such as the world is dangerous and the world is interesting, that correlate with many behaviors and wellbeing-related
variables. We are awarding one$250,000 award and two $125,000 awards that will be administered over 24 months(July1, 2022 to June30,2024) to Principal Investigators proposingto examine primals from any of the following eight disciplinary perspectives: Clinical
Psychology, Positive Psychology, Health Psychology, Organizational Psychology, Political Psychology, Personality Psychology, Social Psychology, and Developmental Psychology.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">LOI due September 26, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: September 14.</span></span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal" style="caret-color: rgb(0, 0, 0);font-variant-caps: normal;orphans: auto;text-align:start;widows: auto;-webkit-text-size-adjust: auto;-webkit-text-stroke-width: 0px;word-spacing:0px">
<b><span style="font-size:12.0pt;font-family:Palatino;color:black"> </span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal" style="caret-color: rgb(0, 0, 0);font-variant-caps: normal;orphans: auto;text-align:start;widows: auto;-webkit-text-size-adjust: auto;-webkit-text-stroke-width: 0px;word-spacing:0px">
<b><span style="font-size:12.0pt;font-family:Palatino;color:black">To search for additional funding opportunities, please visit </span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69"><b><span style="color:red">CoM’s
unofficial funding opportunities blog</span></b></a></span><b><span style="font-size:12.0pt;font-family:Palatino;color:red">.</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
</div>
</body>
</html>